Bone Biologics Research and Development Expenses 2020-2025 | BBLG

Bone Biologics research and development expenses from 2020 to 2025. Research and development expenses can be defined as an expense arising from studies and product development processes.

Bone Biologics Research and Development Expenses 2020-2025 | BBLG

Bone Biologics research and development expenses from 2020 to 2025. Research and development expenses can be defined as an expense arising from studies and product development processes.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$229.4B
Amgen (AMGN)$163.2B
Gilead Sciences (GILD)$142.1B
Vertex Pharmaceuticals (VRTX)$120.3B
Bristol Myers Squibb (BMY)$95.4B
CSL (CSLLY)$86B
GSK (GSK)$76.9B
Regeneron Pharmaceuticals (REGN)$60.3B
Alnylam Pharmaceuticals (ALNY)$43.1B
Argenex SE (ARGX)$36.6B
BioNTech SE (BNTX)$26.8B
Royalty Pharma (RPRX)$21B
Insmed (INSM)$19.9B
Biogen (BIIB)$18.7B
Illumina (ILMN)$17.2B
Incyte (INCY)$15B
Genmab (GNMSF)$14.7B
Genmab (GMAB)$14.5B
Moderna (MRNA)$12.6B
QIAGEN (QGEN)$11.4B
BioMarin Pharmaceutical (BMRN)$11.2B
Swedish Orphan Biovitrum (BIOVF)$10.6B
Ascendis Pharma (ASND)$10B
Exelixis (EXEL)$9.9B
Bio-Techne Corp (TECH)$9.1B
Exact Sciences (EXAS)$9B
Verona Pharma American Depositary Share (VRNA)$9B
Blueprint Medicines (BPMC)$8.3B
Roivant Sciences (ROIV)$7.8B
Legend Biotech (LEGN)$7.5B